November 27, 2017
The "reckless indifference" of a prominent pharmaceutical adviser cost a generic-drug maker exclusive rights to sell a copy of Biogen Inc.'s blockbuster multiple sclerosis drug Tecfidera, according to a new lawsuit filed in New York federal court.